MiMedx Group (MDXG)
(Delayed Data from NSDQ)
$6.97 USD
-0.18 (-2.52%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $6.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDXG 6.97 -0.18(-2.52%)
Will MDXG be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDXG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDXG
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
MDXG: What are Zacks experts saying now?
Zacks Private Portfolio Services
MiMedx (MDXG) Q1 Earnings Match Estimates
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Other News for MDXG
MiMedx Group Breaks Above 200-Day Moving Average - Bullish for MDXG
Decoding MiMedx Group Inc (MDXG): A Strategic SWOT Insight
MiMedx Group (MDXG) Target Price Raised by Cantor Fitzgerald | MDXG Stock News
MiMedx (MDXG) Price Target Raised by Cantor Fitzgerald
MiMedx price target raised by $1 at Cantor Fitzgerald, here's why